Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

Novo released late-stage evidence that its experimental CagriSema injection may outperform its Wegovy obesity drug on weight loss. The item reports a 25% figure in women.

Timeline

1. 20 Oct, 12:50 UTCNovo releases new CagriSema evidence

Top sources

• Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysisCNBC